The U.S. Food and Drug Administration (FDA) approved a supplemental application for Revuforj (revumenib) for efficacy on 2025-10-24. This action, identified as NDA 218944 S-3, was announced by the sponsor SYNDAX.
Background
Revuforj (revumenib) is a drug developed by SYNDAX. Supplemental applications typically involve updates or expansions to an already approved drug's label, often based on new clinical data. This specific supplemental application was classified under Efficacy, indicating new or refined data supporting the drug's effectiveness.
What this means
The FDA's approval of a supplemental application for efficacy for Revuforj suggests that new data has been reviewed and accepted, potentially leading to an expanded or refined understanding of the drug's therapeutic profile. Clinicians and researchers should consult the updated prescribing information for specific details regarding the changes to the drug's approved uses or patient populations.
Source
Information regarding the supplemental approval for Revuforj (revumenib) was obtained from the U.S. Food and Drug Administration (FDA) on 2025-10-24. The details are publicly accessible on the accessdata.fda.gov website, under NDA 218944 S-3.